Company
Every investor coverage indicates participated in a round SK bioscience raised.
Companies SK bioscience acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Jaeyong Ahn | CEO | @AuManufacturing |
Stories naming SK bioscience. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Brisbane vaccine patch maker Vaxxas won a $5.4 million Wellcome grant for studies and a Phase I trial of a typhoid vaccine using its HD-MAP technology, developed with SK bioscience.